{{위키데이터 속성 추적}}
{{Infobox drug
| verifiedrevid = 461115603
| IUPAC_name = 1-(aminomethyl)cyclohexaneacetic acid
| image = Gabapentin2DACS.svg
| width = 200px
| image2 = Gabapentin 3D.png
| width2 = 200px

<!--Clinical data-->
| tradename = Neurontin, others<ref name="Drugs.com"/>
| Drugs.com = {{drugs.com|monograph|gabapentin}}
| MedlinePlus = a694007
| DailyMedID = 52049
| licence_US = Gabapentin
| pregnancy_AU = B1
| pregnancy_US = C
| pregnancy_category =
| legal_AU = S4
| legal_CA = Rx-only
| legal_US = Rx-only
| legal_UK = POM
| routes_of_administration = [[Oral administration|By mouth]]
| class = [[Gabapentinoid]]

<!--Pharmacokinetic data-->
| bioavailability = 27–60% (inversely proportional to dose; a high fat meal also increases bioavailability)<ref name=MSR>{{웹 인용|title = Neurontin, Gralise (gabapentin) dosing, indications, interactions, adverse effects, and more |work = Medscape Reference |publisher = WebMD |access-date = 6 April 2014 |url = http://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011#showall |url-status = live |archive-url = https://web.archive.org/web/20141216215811/http://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011#showall |archive-date = 16 December 2014 }}</ref><ref name = drugs93>{{저널 인용| vauthors = Goa KL, Sorkin EM | title = Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy | journal = Drugs | volume = 46 | issue = 3 | pages = 409–427 | date = September 1993 | pmid = 7693432 | doi = 10.2165/00003495-199346030-00007 }}</ref>
| protein_bound = Less than 3%<ref name = MSR /><ref name = drugs93 />
| metabolism = Not significantly metabolized<ref name = MSR /><ref name = drugs93 />
| elimination_half-life = 5 to 7 hours<ref name = MSR /><ref name = drugs93 />
| excretion = [[Kidney|Renal]]<ref name = MSR /><ref name = drugs93 />

<!--Identifiers -->
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6CW7F3G59X
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 42797
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 940
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 60142-96-3
| ATC_prefix = N03
| ATC_suffix = AX12
| PubChem = 3446
| IUPHAR_ligand = 5483
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00996
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3328
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00332
| PDB_ligand = GBN
| synonyms = CI-945; GOE-3450; DM-1796 (Gralise)

<!--Chemical data-->
| C=9 | H=17 | N=1 | O=2
| molecular_weight = 171.237 g/mol
| SMILES = O=C(O)CC1(CN)CCCCC1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UGJMXCAKCUNAIE-UHFFFAOYSA-N
}}
'''가바펜틴'''(Gabapentin)는(상품명으로 '뉴론틴' 등이 사용된다) 1973년 미국 [[화이자]]사가 개발하여, [[뇌전증]] 및 신경성 통증에 사용되어, 약물과의 상호 작용이 적은 삶의 질을 높이는 [[항경련제]]이다.

== 작용 기전 ==
* 억제성 신경전달물질인 GABA와 구조적인 관련이 있지만 [[감마 아미노뷰티르산|GABA]] 수용체에 작용하지는 않으며, GABA의 uptake나 분해를 억제하지도 않는다.

== 적응증 ==
* 뇌전증 (단독 및 부가 요법제)
* 신경성 통증의 치료

== 각주 ==
{{각주}}

{{항경련제}}
{{토막글|화학}}

[[분류:아미노산]]
[[분류:진통제]]
[[분류:항경련제]]
[[분류:항불안제]]
[[분류:칼슘 통로 차단제]]
[[분류:화이자의 제품]]